NCT01340235

Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Centre Hospitalier Universitaire de Nice · Academic / Other
• Sex: All
• Age: 6 Months – 8 Years
• Healthy volunteers: Not accepted

Summary

Dowling Meara type of epidermolysis bullosa simplex (EBS-DM) is a rare genodermatosis due to keratin 5 and 14 mutation, characterized by skin fragility and spontaneous or post traumatic blisters. Neonatal period and infancy are critical since this autonomic dominant affection usually improves with age. Cyclins seem to be efficient in some cases of EBS but are prohibited in children younger than 8 years old. Erythromycin can be a good alternative in this population due to its antibacterial and anti-inflammatory potential. The aim of this study is the evaluation of the efficiency of oral erythromycin to decrease the number of cutaneous blisters in severe EBS-DM patients from 6 months to 8 years old after 3 months of treatment. Primary end point is the number of patients with decrease of blisters' number of at least 20% after 3 months of treatment by oral erythromycin. It is a preliminary study on 8 patients. Treatment is oral erythromycin twice a day during 3 months. Follow up for each patient is 5 months. The duration of the study is 1 year.

Conditions

• Epidermolysis Bullosa

Interventions

Type	Name	Description
DRUG	Oral erythromycin	Severe Dowling Meara EBS patients from 6 months to 8 years old

Timeline

• Start date: 2011-06-01
• Primary completion: 2011-12-01
• Completion: 2012-06-01
• First posted: 2011-04-22
• Last updated: 2011-10-14

Locations

4 sites across 1 country: France